Antitumor effects of tyropeptin-boronic acid derivatives: New proteasome inhibitors

Area of Science:

• Biochemistry
• Molecular Biology
• Oncology

Background:

• The proteasome is a key regulator of protein degradation, crucial for cellular processes.
• Proteasome inhibitors are effective antitumor agents, with novel derivatives showing promise.
• Tyropeptins and their boronic acid derivatives exhibit potent proteasome inhibitory activity.

Purpose of the Study:

• To evaluate the antitumor effects of two novel tyropeptin-boronic acid derivatives, AS-06 and AS-29.
• To investigate the mechanism of action of these derivatives in multiple myeloma cells.
• To assess the in vivo efficacy of these compounds in a preclinical model.

Main Methods:

• Assessed proteasome activity using proteasome-sensitive fluorescent proteins in HEK293PS cells.
• Analyzed ubiquitinated protein accumulation in human multiple myeloma cells.
• Investigated NF-κB pathway inhibition, apoptosis induction (caspase cascades), and in vivo tumor growth in a xenograft mouse model.

Main Results:

• AS-06 and AS-29 significantly inhibited proteasome activity, suppressing protein degradation.
• These derivatives induced ubiquitinated protein accumulation and inhibited NF-κB activation.
• AS-06 and AS-29 triggered apoptosis via caspase-8 and caspase-9 pathways and suppressed tumor growth in vivo.

Conclusions:

• Tyropeptin-boronic acid derivatives AS-06 and AS-29 demonstrate significant antitumor activity.
• These compounds effectively inhibit the proteasome and NF-κB pathway, leading to apoptosis.
• AS-06 and AS-29 represent promising lead therapeutic agents for human multiple myeloma.